News

German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches. The financial details of the transaction were

The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab). Byooviz is an anti-vascular endothelial growth factor (VEGF)

Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years. The Phase II/III

Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn). Tiancheng Pharmaceutical owns 89.88% of Biotest ordinary

Biocon Biologics Limited (BBL), a subsidiary of Biocon, and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd., has announced a strategic alliance. As

Health Canada has granted full approval to Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty Covid-19 vaccines for use in individuals aged 12 years and above. The regulator originally authorised Moderna’s

Hookipa Pharma has signed a clinical collaboration and supply agreement with Merck to assess HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck squamous

Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19. Under the terms

The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have signed an agreement with Regeneron Pharmaceuticals to buy additional doses of the